StockDuty ← Dashboard Sep 02, 2026 03:47 PM ET
SignalCorporate

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Phase III catalyst for OCU410 targets unmet need in geographic atrophy.

What changed
Why it matters
Phase III catalyst for OCU410 targets unmet need in geographic atrophy.
Sources
eodhd
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →SCOTT BESSENT SURPRISE BOND BUYBACK SPARKS A SILVER RALLY . IS IT TOO LATE TO BUY IN ? →